Navigation Links
Lixte Biotechnology Holdings, Inc. Announces Further Developments Regarding the Anti-Cancer Activity of Its Patent-Pending Proprietary Compounds
Date:2/26/2008

sed patients, such as those with HIV-AIDS or undergoing bone marrow transplantation. Given this lead, Lixte is initiating studies to assess the potential value of these compounds for treatment of serious fungal diseases."

About Lixte Biotechnology Holdings, Inc.:

Lixte Biotechnology Holdings, Inc. (Lixte) is a cancer therapeutics and diagnostics company. Founded as a biomarker-diagnostics company in 2005, Lixte develops new chemotherapy drugs targeting molecular abnormalities of common human cancers. Over the past year, based on the discovery of a new biomarker for brain cancers by collaborators at NIH, the company is working with NINDS, NIH to develop more effective treatments for glioblastoma multiforme (GBM), the most common and most aggressive type of primary brain cancer in adults and other brain cancers of adults and children.

GBM occurs annually in 20,000 to 25,000 adults in the United States and in a comparable number of individuals in Europe. At present, there is no curative treatment known for this disease. Standard treatment involves surgery, radiation and the use of one or more chemotherapeutic agents at the time of initial treatment. At relapse, which occurs in essentially all patients, the present standard treatment is a drug, Temozolomide, which is associated with a modest increase in life span measured in weeks. Thus, there is an urgent need for more effective treatments for GBM.

About the National Institute of Neurological Disorders and Stroke (NINDS), (NIH):

NINDS (http://www.ninds.nih.gov) is a component of the National Institutes of Health (NIH), and is the nation's primary supporter of biomedical research on the brain and nervous system.

The National Institutes of Health (NIH) -- The Nation's Medical Research Agency -- includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. It is the primary federal ag
'/>"/>

SOURCE Lixte Biotechnology Holdings, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Opportunities to Invest in Puerto Rico as Global Center for Biotechnology
2. NxStage Medical to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference on February 7, 2008
3. Medarex to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
4. 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference to Webcast Millennium Presentation
5. Cardinal Health CEO of Clinical & Medical Products to Speak at Merrill Lynchs Global Pharmaceutical, Biotechnology and Medical Device Conference
6. Arena Pharmaceuticals to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
7. MAP Pharmaceuticals to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
8. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at Merrill Lynch 19th Global Pharmaceutical, Biotechnology & Medical Device Conference in New York City
9. Transcept Pharmaceuticals to Present at the 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
10. BD to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
11. Biotechnology Builds a New Heart
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Mike Billings , PT, MS, CEEAA, President ... PT, MBA, GCS, Director of Professional Development to discuss ... of the Improving Medicare Post-Acute Care Transformation Act ... the Infinicast, the two leaders discuss how the IMPACT ... to standardize post-acute assessment data for quality, payment, and ...
(Date:12/24/2014)... HealthDay Reporter TUESDAY, Dec. 23, 2014 ... sex for one year will be allowed to donate blood in ... a 31-year ban on donations from men who have sex with ... intention to release a new draft guidance in early 2015 that ... The FDA is changing its policy based on data from ...
(Date:12/24/2014)... C infection does not contribute to mental decline in people ... have made it possible for people with HIV to survive ... swings and other types of mental impairment as they age, ... with other viruses -- a common problem in people with ... suspects has been the hepatitis C virus, which infects about ...
(Date:12/24/2014)... Adults who experienced childhood abuse or neglect have ... study published online Dec. 24 in the journal ... long-lasting effects, like associated medical and psychological conditions ... director of behavioral medicine at Montefiore Headache Center ... news release. "When managing patients with migraine, ...
(Date:12/24/2014)... HealthDay Reporter WEDNESDAY, Dec. 24, ... start smoking or drinking with each additional symptom they ... new research suggests. "Our findings underscore the ... use as [these] children approach adolescence," said study author ... Group, which is part of Cincinnati Children,s Hospital. "This ...
Breaking Medicine News(10 mins):Health News:Latest Episode of Infinicast Features Infinity Rehab President Discussing IMPACT Act of 2014 and Changes for Post-Acute Therapy Providers in 2015 2Health News:FDA to Lift Ban on Blood Donations by Gay Men 2Health News:FDA to Lift Ban on Blood Donations by Gay Men 3Health News:Hepatitis C Infection Isn't Related to HIV Brain Woes: Study 2Health News:Abuse in Childhood Tied to Migraines in Adulthood 2Health News:ADHD May Raise Teens' Odds for Smoking, Drinking 2Health News:ADHD May Raise Teens' Odds for Smoking, Drinking 3
... to the State, While Market Leader Remains, ... Report from HealthLeaders-InterStudy, NASHVILLE, Tenn., Feb. 11 ... intelligence, reports that pay-for-,performance programs have yet to ... Health Plan Analysis, the state,s local major insurer, ...
... Senior Living Inc.,(NYSE: BKD ) (the "Company") today ... the Company,s Board of Directors,effective February 7, 2008. In ... his position as Co-CEO, and will no longer serve ... Sheriff, Brookdale,s Co-CEO,will remain as the sole Chief Executive ...
... popularity amongst,British men and women to travel to Malaysia ... at an enormous rate - leading,operator Gorgeous Getaways witnessed ... in 2007., The reasons for travelling to ... 75% less than at home), 2. Quality (accredited ...
... LONDON, February 11 Amarin Corporation plc,(NASDAQ: ... notification from The,Nasdaq Stock Market that the Company ... bid price requirement for continued listing on the ... In,the notification, Nasdaq advised that the Company has ...
... SALT LAKE CITY, Feb. 11 Two Little Hands ... the hit public television,show designed to teach babies, toddlers ... -- will debut its second season at this,year,s Toy ... (Photo: http://www.newscom.com/cgi-bin/prnh/20080211/LAM029 ), Like the ...
... loving our reefs to death? Florida biochemist says coral-killing ... synthetics harm humans, ... coral reefs,choose your sunscreen wisely, Florida biochemist Celia Ferreira, Ph.D.,advises., ... 4,000 to 6,000 tons of sunscreen that wash off swimmers every,year., ...
Cached Medicine News:Health News:Pay-For-Performance Not Getting a Red-Carpet Reception in Arizona 2Health News:Brookdale Senior Living Announces Changes in Senior Management and Board of Directors 2Health News:Surgery Holidays to Malaysia - British Women Tell Their Stories 2Health News:Amarin Regains Compliance With Nasdaq Listing Requirements 2Health News:Two Little Hands Productions, Creators of Popular Children's TV Series Signing Time, Debuts Second Season at This Year's Toy Fair 2008 2Health News:Choose Biodegradable Sunscreen to Save Coral Reefs 2
(Date:12/24/2014)... China, Dec. 24, 2014 /PRNewswire/  -- Tianyin Pharmaceutical ... pharmaceutical company that specializes in the patented biopharmaceutical, ... active pharmaceutical ingredients (API) released unaudited preliminary financial ... 2015. Fiscal Year 2015 Ended September ... $9.7 million compared with $14.7 million in 1Q14 ...
(Date:12/24/2014)... , Dec. 24, 2014  The International Trade Commission (ITC) ... (RMD) against BMC Medical. In a notice issued on December ... that ResMed,s patent on its humidifier was invalid. ... "monumental win". "We are very excited with the ITC,s decision ... that we have taken since the very beginning on the ...
(Date:12/24/2014)... FARMINGTON, Conn. , Dec. 24, 2014 ... a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics ... medical need and commercial potential, today announced that ... 2,050,000 shares of its common stock and Series ... common stock.  Funds under the management of QVT ...
Breaking Medicine Technology:TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 2TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 3TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 4TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 5TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 6TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 7TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 8TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 9TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 10TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 11TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 12ITC Final Decision Goes Against ResMed (RMD) Monumental Win for 3B/BMC 2Palatin Completes $20 Million Equity and $10 Million Debt Financings 2Palatin Completes $20 Million Equity and $10 Million Debt Financings 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 4
Medium clip size, 10mm...
... in 10mm and 5mm sizes. Our market-leading ... placement., ,The LIGACLIP ERCA Endoscopic Rotating ... patient use instrument designed to provide a ... The instrument delivers 20 titanium clips that ...
... utilizes turbidimetric immunoassay methodology which is a ... of 0.2-28.0 mg/dL. This assay is homogeneous, ... clinical chemistry analyzers. The Wako CRP-HS assay ... linearity, correlation, and sensitivity. Expected values are ...
... Piccolo is the first compact, broad menu ... testing in any treatment setting. Care givers ... panels with less than one minute of ... comparable in quality to larger, expensive laboratory ...
Medicine Products: